Holly K. Tabor, PhD and Aaron Goldenberg, PhD, MPH
Rare genetic disease research has something to teach precision medicine about addressing some patients’ limited access to treatment. Health disparities exacerbated by high costs and limited availability of drugs can, perhaps, be mitigated when patient activism accelerates drug development.
AMA J Ethics. 2018;20(9):E834-840. doi:
10.1001/amajethics.2018.834.
The allocation of scarce resources, such as HLA platelets, involves a conflict between the medical ethics principles of beneficence and social justice.
AMA J Ethics. 2016;18(8):764-770. doi:
10.1001/journalofethics.2016.18.8.ecas1-1608.
After years of funding disease-specific treatment, donation trends have shifted to support broader health systems infrastructure development. A remaining challenge is how to sustain antiretroviral therapy (ART) for patients in resource-poor regions.
AMA J Ethics. 2016;18(7):681-690. doi:
10.1001/journalofethics.2016.18.7.ecas3-1607.
Jennifer T. McIntosh, PhD, RN, CNE, PMH-BC, NEA-BC and Mona Shattell, PhD, RN
This commentary examines prevention policies that overly rely on liberty restrictions imposed by designs of inpatient psychiatric units’ structures and spaces.
AMA J Ethics. 2024;26(3):E199-204. doi:
10.1001/amajethics.2024.199.
Therapeutic security in inpatient psychiatric settings requires careful planning and implementation if it is to support both patients’ safety and dignity.
AMA J Ethics. 2024;26(3):E205-211. doi:
10.1001/amajethics.2024.205.